Song Y, He K, Levitan E B, Manson J E, Liu S
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Diabet Med. 2006 Oct;23(10):1050-6. doi: 10.1111/j.1464-5491.2006.01852.x.
The aim of this study was to assess the evidence on the effect of oral magnesium supplementation on glycaemic control in patients with Type 2 diabetes.
We searched the electronic databases of medline, embase and the Cochrane Controlled Trials Register up to January 2005. We identified nine randomized double-blind controlled trials with a total of 370 patients with Type 2 diabetes and of duration 4-16 weeks. The median dose of oral magnesium supplementation was 15 mmol/day (360 mg/day) in the treatment groups. The primary outcome was glycaemic control, as measured by glycated haemoglobin (HbA(1c)) or fasting blood glucose levels; the secondary outcomes included body mass index, blood pressure (BP) and lipids. Using a random-effects model, we calculated the weighted mean differences (WMD) and 95% confidence interval (CI).
After a median duration of 12 weeks, the weighted mean post-intervention fasting glucose was significantly lower in the treatment groups compared with the placebo groups [-0.56 mmol/l (95% CI, -1.10 to -0.01); P for heterogeneity = 0.02]. The difference in post-intervention HbA(1c) between magnesium supplementation groups and control groups was not significant [-0.31% (95% CI, -0.81 to 0.19); P for heterogeneity = 0.10]. Neither systolic nor diastolic BP was significantly changed. Magnesium supplementation increased on high-density lipoprotein (HDL) cholesterol levels [0.08 mmol/l (95% CI, 0.03 to 0.14); P for heterogeneity = 0.36] but had no effect on total cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride.
Oral magnesium supplementation for 4-16 weeks may be effective in reducing plasma fasting glucose levels and raising HDL cholesterol in patients with Type 2 diabetes, although the long-term benefits and safety of magnesium treatment on glycaemic control remain to be determined.
本研究旨在评估口服补充镁对2型糖尿病患者血糖控制效果的证据。
我们检索了截至2005年1月的医学期刊数据库（Medline）、荷兰医学文摘数据库（Embase）和考科蓝对照试验注册库的电子数据库。我们确定了9项随机双盲对照试验，共有370例2型糖尿病患者，试验持续时间为4 - 16周。治疗组口服补充镁的中位剂量为15 mmol/天（360 mg/天）。主要结局是通过糖化血红蛋白（HbA1c）或空腹血糖水平衡量的血糖控制情况；次要结局包括体重指数、血压（BP）和血脂。使用随机效应模型，我们计算了加权平均差（WMD）和95%置信区间（CI）。
在中位持续时间12周后，与安慰剂组相比，治疗组干预后的加权平均空腹血糖显著降低[-0.56 mmol/L（95% CI，-1.10至-0.01）；异质性P = 0.02]。补充镁组与对照组干预后HbA1c的差异不显著[-0.31%（95% CI，-0.81至0.19）；异质性P = 0.10]。收缩压和舒张压均无显著变化。补充镁可提高高密度脂蛋白（HDL）胆固醇水平[0.08 mmol/L（95% CI，0.03至0.14）；异质性P = 0.36]，但对总胆固醇、低密度脂蛋白（LDL）胆固醇和甘油三酯无影响。
口服补充镁4 - 16周可能对降低2型糖尿病患者的空腹血糖水平和提高HDL胆固醇有效，尽管镁治疗对血糖控制的长期益处和安全性仍有待确定。
